1 Study Coverage
1.1 Molecular Diagnostics and NAT Revenue in Molecular Diagnostics and NAT Business (2017-2022) & (US$ Million) Introduction
1.2 Global Molecular Diagnostics and NAT Outlook 2017 VS 2022 VS 2028
1.2.1 Global Molecular Diagnostics and NAT Market Size for the Year 2017-2028
1.2.2 Global Molecular Diagnostics and NAT Market Size for the Year 2017-2028
1.3 Molecular Diagnostics and NAT Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.3.1 The Market Share of United States Molecular Diagnostics and NAT in Global, 2017 VS 2022 VS 2028
1.3.2 The Growth Rate of Molecular Diagnostics and NAT Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4 Molecular Diagnostics and NAT Market Dynamics
1.4.1 Molecular Diagnostics and NAT Industry Trends
1.4.2 Molecular Diagnostics and NAT Market Drivers
1.4.3 Molecular Diagnostics and NAT Market Challenges
1.4.4 Molecular Diagnostics and NAT Market Restraints
1.5 Study Objectives
1.6 Years Considered
2 Molecular Diagnostics and NAT by Type
2.1 Molecular Diagnostics and NAT Market Segment by Type
2.1.1 Amplification Technologies
2.1.2 Amplified Gene Detection Technologies
2.1.3 DNA And Oligonucleotide Microarrays
2.1.4 Gene Sequencing
2.2 Global Molecular Diagnostics and NAT Market Size by Type (2017, 2022 & 2028)
2.3 Global Molecular Diagnostics and NAT Market Size by Type (2017-2028)
2.4 United States Molecular Diagnostics and NAT Market Size by Type (2017, 2022 & 2028)
2.5 United States Molecular Diagnostics and NAT Market Size by Type (2017-2028)
3 Molecular Diagnostics and NAT by Application
3.1 Molecular Diagnostics and NAT Market Segment by Application
3.1.1 Hospitals and Clinics
3.1.2 Research Institutes
3.1.3 Diagnostic Centers
3.2 Global Molecular Diagnostics and NAT Market Size by Application (2017, 2022 & 2028)
3.3 Global Molecular Diagnostics and NAT Market Size by Application (2017-2028)
3.4 United States Molecular Diagnostics and NAT Market Size by Application (2017, 2022 & 2028)
3.5 United States Molecular Diagnostics and NAT Market Size by Application (2017-2028)
4 Global Molecular Diagnostics and NAT Competitor Landscape by Company
4.1 Global Molecular Diagnostics and NAT Market Size by Company
4.1.1 Top Global Molecular Diagnostics and NAT Companies Ranked by Revenue (2021)
4.1.2 Global Molecular Diagnostics and NAT Revenue by Player (2017-2022)
4.2 Global Molecular Diagnostics and NAT Concentration Ratio (CR)
4.2.1 Molecular Diagnostics and NAT Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Companies of Molecular Diagnostics and NAT in 2021
4.2.3 Global Molecular Diagnostics and NAT Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Molecular Diagnostics and NAT Headquarters, Revenue in Molecular Diagnostics and NAT Business (2017-2022) & (US$ Million) Type
4.3.1 Global Molecular Diagnostics and NAT Headquarters and Area Served
4.3.2 Global Molecular Diagnostics and NAT Companies Revenue in Molecular Diagnostics and NAT Business (2017-2022) & (US$ Million) Type
4.3.3 Date of International Companies Enter into Molecular Diagnostics and NAT Market
4.4 Companies Mergers & Acquisitions, Expansion Plans
4.5 United States Molecular Diagnostics and NAT Market Size by Company
4.5.1 Top Molecular Diagnostics and NAT Players in United States, Ranked by Revenue (2021)
4.5.2 United States Molecular Diagnostics and NAT Revenue by Players (2020, 2021 & 2022)
5 Global Molecular Diagnostics and NAT Market Size by Region
5.1 Global Molecular Diagnostics and NAT Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Molecular Diagnostics and NAT Market Size by Region (2017-2028)
5.2.1 Global Molecular Diagnostics and NAT Market Size by Region: 2017-2022
5.2.2 Global Molecular Diagnostics and NAT Market Size by Region (2023-2028)
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Molecular Diagnostics and NAT Market Size YoY Growth 2017-2028
6.1.2 North America Molecular Diagnostics and NAT Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Molecular Diagnostics and NAT Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Molecular Diagnostics and NAT Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Molecular Diagnostics and NAT Market Size YoY Growth 2017-2028
6.3.2 Europe Molecular Diagnostics and NAT Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Molecular Diagnostics and NAT Market Size YoY Growth 2017-2028
6.4.2 Latin America Molecular Diagnostics and NAT Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Molecular Diagnostics and NAT Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Molecular Diagnostics and NAT Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 UAE
7 Company Profiles
7.1 Roche
7.1.1 Roche Company Details
7.1.2 Roche Business Overview
7.1.3 Roche Molecular Diagnostics and NAT Introduction
7.1.4 Roche Revenue in Molecular Diagnostics and NAT Business (2017-2022)
7.1.5 Roche Recent Development
7.2 Abbott
7.2.1 Abbott Company Details
7.2.2 Abbott Business Overview
7.2.3 Abbott Molecular Diagnostics and NAT Introduction
7.2.4 Abbott Revenue in Molecular Diagnostics and NAT Business (2017-2022)
7.2.5 Abbott Recent Development
7.3 BD
7.3.1 BD Company Details
7.3.2 BD Business Overview
7.3.3 BD Molecular Diagnostics and NAT Introduction
7.3.4 BD Revenue in Molecular Diagnostics and NAT Business (2017-2022)
7.3.5 BD Recent Development
7.4 Biomerieux
7.4.1 Biomerieux Company Details
7.4.2 Biomerieux Business Overview
7.4.3 Biomerieux Molecular Diagnostics and NAT Introduction
7.4.4 Biomerieux Revenue in Molecular Diagnostics and NAT Business (2017-2022)
7.4.5 Biomerieux Recent Development
7.5 Qiagen
7.5.1 Qiagen Company Details
7.5.2 Qiagen Business Overview
7.5.3 Qiagen Molecular Diagnostics and NAT Introduction
7.5.4 Qiagen Revenue in Molecular Diagnostics and NAT Business (2017-2022)
7.5.5 Qiagen Recent Development
7.6 Thermo Fisher Scientific
7.6.1 Thermo Fisher Scientific Company Details
7.6.2 Thermo Fisher Scientific Business Overview
7.6.3 Thermo Fisher Scientific Molecular Diagnostics and NAT Introduction
7.6.4 Thermo Fisher Scientific Revenue in Molecular Diagnostics and NAT Business (2017-2022)
7.6.5 Thermo Fisher Scientific Recent Development
7.7 Agilent
7.7.1 Agilent Company Details
7.7.2 Agilent Business Overview
7.7.3 Agilent Molecular Diagnostics and NAT Introduction
7.7.4 Agilent Revenue in Molecular Diagnostics and NAT Business (2017-2022)
7.7.5 Agilent Recent Development
7.8 GenMark
7.8.1 GenMark Company Details
7.8.2 GenMark Business Overview
7.8.3 GenMark Molecular Diagnostics and NAT Introduction
7.8.4 GenMark Revenue in Molecular Diagnostics and NAT Business (2017-2022)
7.8.5 GenMark Recent Development
7.9 Siemens Healthcare
7.9.1 Siemens Healthcare Company Details
7.9.2 Siemens Healthcare Business Overview
7.9.3 Siemens Healthcare Molecular Diagnostics and NAT Introduction
7.9.4 Siemens Healthcare Revenue in Molecular Diagnostics and NAT Business (2017-2022)
7.9.5 Siemens Healthcare Recent Development
7.10 AutoGenomics
7.10.1 AutoGenomics Company Details
7.10.2 AutoGenomics Business Overview
7.10.3 AutoGenomics Molecular Diagnostics and NAT Introduction
7.10.4 AutoGenomics Revenue in Molecular Diagnostics and NAT Business (2017-2022)
7.10.5 AutoGenomics Recent Development
8 Research Findings and Conclusion
9 Appendix
9.1 Research Methodology
9.1.1 Methodology/Research Approach
9.1.2 Data Source
9.2 Author Details
9.3 Disclaimer
